When hormone therapy for prostate cancer stops working, the cancer has learned to grow even with very low testosterone levels. Doctors call this castration-resistant prostate cancer, or CRPC. It’s a significant turning point, but it’s not the end of the road. Multiple treatment options exist beyond first-line hormone therapy, and many people live years after reaching this stage, with a median overall survival of about 33 months and roughly 20% of patients still alive at the five-year mark.
How You Know Hormone Therapy Is Failing
The main signal is a rising PSA level despite ongoing hormone treatment. Your testosterone stays at very low levels, but the cancer finds ways to keep growing. Doctors track not just whether PSA is rising but how fast it’s rising, because the speed matters enormously for prognosis. A PSA doubling time (how long it takes your PSA number to double) shorter than 12 months is associated with a 50% risk of dying from prostate cancer within five years of relapse, compared to just 10% for men whose PSA doubles more slowly.
When the doubling time drops below three months, the risk jumps dramatically, carrying a hazard ratio of 25 compared to slower-growing disease. That’s far more predictive than tumor grade alone. So if your doctor seems focused on the pace of PSA change rather than the absolute number, that’s why.
Physical symptoms often accompany or follow the PSA rise. The most common is bone pain, particularly in the back, hips, and pelvis, that tends to worsen over time. Prostate cancer that has become resistant to hormone therapy most frequently spreads to bones and lymph nodes, and less commonly to the liver and lungs. Deepening fatigue, unintentional weight loss, increased urinary frequency or pain with urination, and nausea can all signal progression.
Why the Cancer Stops Responding
Hormone therapy works by starving prostate cancer cells of testosterone. Over time, cancer cells evolve workarounds. Understanding this helps explain why the next treatments target different vulnerabilities.
The most common adaptation involves the androgen receptor, the protein on cancer cells that testosterone binds to. In untreated prostate cancer, mutations in this receptor are extremely rare. But in castration-resistant disease, more than 10% of tumors carry receptor mutations, and that number climbs further in men who’ve been on anti-androgen drugs. Some of these mutations are remarkably cunning: they widen the receptor’s sensitivity so that other hormones like estrogen or progesterone can activate it. Others actually convert anti-cancer drugs into growth signals, essentially turning the treatment into fuel.
Cancer cells can also produce shortened, truncated versions of the androgen receptor that lack the part where hormones normally dock. These truncated receptors are permanently switched on, driving cancer growth with no testosterone required at all. One variant in particular is found at much higher levels in castration-resistant disease than in hormone-sensitive disease and is linked to shorter survival. Ironically, some treatments can actually increase production of these truncated receptors, which is one reason why sequencing of therapies matters.
Next-Generation Hormone Therapies
Even after standard hormone therapy fails, the cancer often still depends on androgen receptor signaling to some degree. Two drugs target this pathway more aggressively. One blocks the production of androgens throughout the body (not just in the testes). The other binds to the androgen receptor more tightly than older drugs and prevents it from entering the cell nucleus where it would activate growth genes.
The order in which these are used matters. Clinical trial data shows that using one of these agents second, after the other has already failed, produces very different response rates depending on the sequence. In a crossover trial, 36% of patients responded to the receptor blocker as a second-line treatment, while only 4% responded to the androgen production blocker used second. Your oncologist will factor this into planning.
Chemotherapy Options
Chemotherapy with a taxane-based drug has been a standard treatment for castration-resistant prostate cancer since 2004, when it became the first therapy to improve overall survival in this setting. A related drug was approved in 2010 specifically for patients whose cancer progressed after the first chemotherapy. Recent data suggests that repeating the original chemotherapy rather than switching to the newer agent may actually produce better outcomes in some patients, with a median overall survival of 12.5 months versus 9.6 months.
Chemotherapy at this stage isn’t curative, but it can shrink tumors, reduce pain, and extend life. Side effects like fatigue, lowered blood counts, and neuropathy (tingling or numbness in hands and feet) are real considerations, and your oncologist will weigh your overall fitness and preferences when recommending timing.
Targeted Radioligand Therapy
One of the more recent advances is a treatment that delivers radiation directly to cancer cells wherever they are in the body. It works by attaching a radioactive molecule to a compound that seeks out a protein called PSMA, which sits on the surface of most prostate cancer cells. The radiation is delivered precisely to the tumor while largely sparing surrounding tissue.
In a landmark trial published in the New England Journal of Medicine, this approach extended median overall survival from 11.3 months to 15.3 months compared to standard care alone, and more than doubled the time before the cancer visibly progressed on scans (8.7 versus 3.4 months). To qualify, patients need to have already tried both a next-generation hormone therapy and at least one round of chemotherapy, and a specialized PET scan must confirm that the cancer cells carry enough of the PSMA target protein. Not all tumors do, so the imaging step is essential.
Genetic Testing and Precision Therapies
About 23% of men with castration-resistant prostate cancer carry mutations in genes responsible for DNA repair, including BRCA1, BRCA2, and several others. A larger screening effort found qualifying genetic alterations in 28% of patients tested. These mutations make cancer cells less able to fix their own DNA, which creates a therapeutic opening.
Drugs called PARP inhibitors exploit this weakness by blocking the cancer cell’s backup DNA repair system, effectively causing the cell to accumulate so much genetic damage that it dies. The FDA has approved one of these drugs for castration-resistant patients with specific gene alterations who’ve already progressed on next-generation hormone therapy. Genetic testing, either from a blood sample or tumor biopsy, is now a routine recommendation after hormone therapy fails because it directly determines whether you’re eligible for this class of treatment.
Protecting Your Bones
Bone is the most common site of metastasis in castration-resistant prostate cancer, and skeletal complications like fractures, spinal cord compression, and the need for radiation to bone are major sources of disability. Two types of bone-protecting agents are used to reduce these events. One is an antibody given as a shot under the skin every four weeks that blocks a protein involved in bone breakdown. The other is an intravenous infusion on the same schedule.
In a large international trial comparing the two, the antibody approach proved more effective at preventing skeletal complications. Both are given alongside calcium and vitamin D supplements. These treatments don’t fight the cancer directly, but they can meaningfully reduce pain and preserve mobility, which matters enormously for quality of life.
How Treatments Are Sequenced
There is no single path through castration-resistant prostate cancer. Treatment sequencing depends on your symptoms, how fast the cancer is progressing, your overall health, genetic test results, and what you’ve already received. Some men start with a next-generation hormone therapy, then move to chemotherapy, then potentially radioligand therapy. Others may receive chemotherapy first if they have rapidly progressing or symptomatic disease.
What’s changed in recent years is the number of options available. A decade ago, the choices after hormone therapy failure were limited. Today, there are multiple distinct classes of treatment, each attacking the cancer through a different mechanism. Many patients cycle through three, four, or even five lines of therapy. The 28% of patients alive at five years in large community-practice data reflects this expanding treatment landscape. Each transition between therapies is a decision point worth discussing thoroughly with your oncologist, because the order and timing of these treatments can affect how well later ones work.